Therefore, blocking PI3K/AKT/mTOR and the cell cycle pathway may be helpful for risk score-high breast cancer patients, and the subsequent drug-sensitive analysis targeted to these pathways confirmed this. This evidence concerns the gene MTOR and breast carcinoma.